Abstract: A improved method of treating pain is disclosed. The method includes administering to a subject an N-type voltage-sensitive calcium channel blocking omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. The method includes administering the omega conopeptide epidurally, preferably so that the compound is in prolonged or sustained contact with the epidural region.

Abstract: Novel short peptides are disclosed which are selected from the group consisting of TAVTQTYGGNSNGEP and fragments thereof containing the minimal sequence TAVTQTY. These peptides are antithrombotic agents and mediate divalent cation-independent adhesion of platelets to fibronectin.

Abstract: A nasally administrable composition having a physiologically active peptide dispersed homogeneously in and adsorbed homogeneously onto a unique carrier. The composition contains an effective amount of physiologically active peptide dispersed homogeneously in and adsorbed homogeneously onto a mucosa protecting and/or tissue repairing agent, e.g., gefarnate, aceglutamide aluminum, sucralfate, L-glutamine, sofalcone, teprenone, plaunotol, rebamipide, aldioxa, cetraxate or troxipide.

Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha. (.omega.-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha. (.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

Abstract: Analogs of SRIF which are selective for SSTR1 in contrast to the other cloned SRIF receptors. These analogs are useful in determining the tissue and cellular expression of the receptor SSTR1 and its biological role in the endocrine, exocrine and nervous system, as well as in regulating tumor growth. SRIF analog peptides, such as des-AA.sup.1,2,5 ?D-Trp.sup.8, IAmp.sup.9 !-SRIF inhibit the binding of ?.sup.125 I-Tyr.sup.11 !SRIF to the cloned human receptor SSTR1 but do not bind to mouse SSTR2 and SSTR3, human SSTR4 or rat SSTR5. By incorporating an iodinated tyrosine in position-2 in these selective SRIF analogs, a labelled compound useful in drug-screening methods is provided.

Abstract: The present invention is directed to a purification method for hydrophobic polypeptides by using high performance liquid chromatography, characterized by using a mixed solvent as a moving phase, in which the portion of trifluoroacetic acid is from 3 to 10% by volume, and polyvinyl alcohol-based column filler in the said high performance liquid chromatography. The method according to the present invention is useful as a purification method for hydrophobic polypeptides in view of the fact that the pulmonary surfactant, which is prepared from the hydrophobic polypeptide purified according to the method of the present invention, shows better surface active property than the hydrophobic polypeptides purified by customary methods for the purification.